Clinical Trial Update: Bryostatin Treatment of Moderately Severe Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of bryostatin for moderately severe Alzheimer's disease has completed, with the results posted in July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Bryostatin-1 (bryostatin-1)

Snippet

Sponsor: Neurotrope Bioscience, Inc. | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-07-31